A rare disease group reconsiders the possible; health insurers fight proposed changes to Medicare Advantage

What do you do when the years of fundraising and lobbying and research actually pay off? A rare disease group confronts the question.

March 27, 2023 Check out STAT+

Sponsored By

Courtesy Eakin family With arrival of breakthrough therapies, a rare disease group reconsiders the possible — and its mission A new age of genetic medicine is forcing patients and researchers to confront a blessed question: What happens when treatment finally comes? By Jason Mast STAT+ | Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the stakes Insurers are distorting the reality of the proposals in a bid to protect the sizable and growing profits they earn from Medicare Advantage. By Bob Herman Newly available test strips can detect lethal 'tranq' in drug supply The sedative is increasingly common in the U.S. illicit-drug supply — especially in Philadelphia, but increasingly in other cities, too. By Lev Facher Trisha Ahmed/AP As states ban gender-affirming care, Minnesota aims to be a refuge for trans youth Minnesota is looking to establish itself as a "trans refuge state" for young people seeking gender-affirming care. By Theresa Gaffney STAT+ | Bernie Sanders' accidentally great drug pricing idea What, Bernie Sanders asked recently, if the government paid for companies' research, enough to ensure they make a reasonable profit? By Matthew Herper STAT+ | Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS FDA officials have promised to apply the "broadest regulatory flexibility" to ALS drug reviews, even for therapies with uncertain benefit. By Adam Feuerstein APStock STAT+ | Ohio attorney general accuses pharmacy benefit managers of drug price fixing The Ohio attorney general filed a lawsuit on Monday accusing three large pharmacy benefit managers of fixing prices on some drugs. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser